CN100374139C - Chinese medicine compound preparation for treating hyperthyoidism - Google Patents
Chinese medicine compound preparation for treating hyperthyoidism Download PDFInfo
- Publication number
- CN100374139C CN100374139C CNB2005100960524A CN200510096052A CN100374139C CN 100374139 C CN100374139 C CN 100374139C CN B2005100960524 A CNB2005100960524 A CN B2005100960524A CN 200510096052 A CN200510096052 A CN 200510096052A CN 100374139 C CN100374139 C CN 100374139C
- Authority
- CN
- China
- Prior art keywords
- hyperthyroidism
- rate
- thyroid
- treatment
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a Chinese medicinal preparation--Jiazhuangling for treating hyperthyroidism, thyroma, thyroid cyst and endemic goiter. The preparation has obvious effect, short course of treatment, low relapse rate and dismission of the trouble of taking medicines for a long time. 218 cases of patients with various kinds of hyperthyroidism are observed in clinic, and the patients can be cured within three months. The preparation can cure thyroma, thyroid cyst, endemic goiter, etc. within two months. The total effective rate is 98.6%, the cure rate is 90.8%, the ineffective rate is 1.4%, and the relapse rate within five years is only 1.8%.
Description
Technical field:
The present invention relates to a kind ofly can treat hyperthyroidism, Chinese medicine preparation strumous, belonging to plant is raw-material field of medicine preparations.
Background technology:
Hyperthyroidism (hyperthyroidism) and goiter sickness rate height in the crowd does not still have specific etiological treatment at present, and treatment is primarily aimed at hyperthyroidism itself.The treatment hyperthyroidism has the three major types therapy usually---oral antithyroid drug, radioiodine and operative treatment.Generally speaking, the doctor of the U.S. is than the preference radioiodine therapy, and the doctor of Europe and Japan is the preference antithyroid drug then.
One, Drug therapy utilizes Thiourea medicine (methylthiouracil, propylthiouracil, thiamazole, hyperthyroidism equality) to suppress the synthetic of thyroxin.Patient Ke Jia beta-blocker propranolol or metoprolol that the treatment initial stage is fast to heart rate.Drug therapy must be checked T3, T4, TSH, liver function etc. in every month, to adjust the dosage of antithyroid drug.Excessive as drug dose, can cause thyroid function low; Then hyperthyroidism symptom of underdosage can not be controlled, and hyperthyroidism symptom long-term control is bad, can cause hyperthyroid heart disease, cardiac dilatation, atrial fibrillation and heart failure etc.For preventing granulocytopenia, need have a blood test weekly conventional 1~2 time. the course of treatment at least 1~1.5 year.The minimizing of side effect granulocyte, liver function injury, erythra etc.Relapse rate is higher after the drug withdrawal, the past report is about 50%, in recent years on the rise, external report can be up to 80%, reason is unclear, may increase relevant with the iodine of taking in. according to the huang jiasi surgery record, simple medication has 65% patient not resume work, and being reported as 50% patient in recent years can not resume work.
Two, radioiodine therapy utilizes thyroid to have to concentrate the ability and the radioiodine of iodine can discharge Beta-ray effect, makes that follicular epithelial cell destroys, atrophy, and the secretion thyroxin reduces, and reaches therapeutic purposes.Most patients only need take primary emission iodine, and about 20% patient need carry out two to three treatments.With regard to the radioiodine therapy hyperthyroidism, the thyroid volume in treatment back can dwindle gradually, hypothyroidism (hypothyroidism) occurs, external report hypothyroidism incidence rate is very high, 1 year is 20%, treat in back 20 years be 20~80%. domestic reports 2~5 years be 25%, 6~10 years be 50%; It was 5% in 1 year that report is also arranged, and later average annual growth 1~2%. does not still have the method for its generation of prevention at present, can only give thyroxin lifelong replacement therapy. also can bring out thyroid storm or increase the weight of infiltrative exophthalmos for individual patient.Following situation is not suitable for this treatment: 1. trimester of pregnancy, age of sucking; 2. the age is person below 20 years old; 3. peripheral blood leukocyte<3000/ cubic millimeter or neutral<1500/ cubic millimeter; 4. the severe heart, liver, renal failure; 5. severe infiltrative exophthalmos; 6. hyperthyroidism crisis.
Three, relapse rate is low after the operative treatment subtotal thyroidectomy, but operation is destructive irreversible treatment, and can cause some complication, needs the careful selection case.For preceding two classes treatment, the danger of operative treatment is big, the expense height.Cut and lacked the postoperative hyperthyroidism and recur easily, cut many and hypothyroidism occurred.Main complication is that parathyroid injury causes parathyroid gland and recurrent nerve injury, and incidence rate is for respectively being 1%~2%.Postoperative hyperthyroidism relapse rate is about 10%.The person has to be not suitable for the operative treatment: 1. infiltrative exophthalmos person; 2. severe cardiac, liver, kidney, lung complication, whole body situation difference can not tolerate surgery person; 3. first trimester and back three months; 4. light disease patient estimates that Drug therapy can alleviation person.
Hyperthyroidism is still anosis because of treatment. and there are tens million of patients in China, strictly says, the effect of three kinds of conventional treatments is all undesirable.
Motherland's medical science is to the understanding of thyroid disease: thyroid disease belongs to wart disease in motherland's medical science; Hemangioma of the neck is arranged, goiter due to disorder of QI, toxic goiter, melancholy wart, stony goiter, labor wart, titles such as native wart and muscle wart.Wherein with hyperthyroidism nearer toxic goiter, goiter due to disorder of QI, melancholy wart arranged.Still had palpitation, palpitation with a distress feeling etc. in addition.
The cause of disease: 1. exopathogenic factor: water and soil is inappropriate, exopathogen invasion and attack, the evil poison of six climate exopathogens, invade body, interior impairment of ZANG FU-organs etc.
2. endogenous cause of ill: the natural endowment deficiency, the kidney being the origin of congenital constitution, and deficiency of kidney yin can cause excessive rising of liver-YANG; Insufficiency of kidney-YANG, failure of qi transforming fluid is for expectorant is drink.Conditioning mistake day after tomorrow degree is as feelings will internal injury, eating and drinking without temperance etc.Feelings will internal injury mostly is depressed rage impairing the liver, obstruction of QI, and fire-transformation is given birth to heat, and perverse and unreasonable manner is violated spleen, causes humidogene expectorant.
Pathogenesis: under multiple paathogenic factor effect, the five internal organs all can be got involved, and are the most obvious with Liver and kidney.Feelings will internal injury causes qi depression to blood stasis, the phlegm-damp cohesion.Stagnation of liver-QI is not relaxed, and gas is rate blood not, causes the expectorant blood coagulation stasis of blood.Stagnated QI transforming into fire must not be led off, the moon of must feeling frustrated.Basic pathogenesis is a basis with the deficiency of YIN or yang deficiency, and gas, fire, expectorant, the stasis of blood are basic factor with gas, expectorant again wherein for mark.
Summary of the invention:
The objective of the invention is to remedy the deficiencies in the prior art part, and provide a kind of evident in efficacy, the desirable medicine of treatment hyperthyroidism, thyroid tumor, thyroid cyst and the endemic goiter that has no side effect.
The specific embodiment:
The present invention realizes in the following way:
It is characterized in that the raw material of making active ingredient by following proportioning is:
Sargassum 10%~30% Thallus Laminariae (Thallus Eckloniae) 10%~30% Spica Prunellae 10%~30%
Semen Sinapis Albae 10%~30% Rhizoma Dioscoreae Bulbiferae 10%~30% Bulbus Fritillariae Thunbergii 10%~30%
Herba Taraxaci 10%~30% Radix Salviae Miltiorrhizae 10%~30%
The Chinese medicine preparation that the Chinese medicine of above-mentioned component makes with conventional production method can be powder, capsule, close ball, electuary, oral liquid and injection etc.
This Chinese medicine preparation prescription is inventor's secret recipe handed down in the family.Wherein: Sargassum, Thallus Laminariae (Thallus Eckloniae), Rhizoma Dioscoreae Bulbiferae and the Semen Sinapis Albae softening the hard mass that eliminates the phlegm, the eliminating stagnation wart that disappears is monarch; Spica Prunellae regulate the flow of vital energy resolving depression, relieving inflammation or internal heat is minister; The Radix Salviae Miltiorrhizae activating blood circulation and dissipating phlegm is assistant; Herba Taraxaci heat-clearing and toxic substances removing, dispersing swelling and dissipating binds are for making.All medicines are played the merit of the resolving depression of regulating the flow of vital energy, clearing away phlegm softening the hard mass, blood circulation promoting and dispersing pathogen accumulation, heat-clearing and toxic substances removing altogether.
The present invention and prior art relatively have the following advantages:
1, the trouble that Chinese medicine preparation of the present invention treatment thyroid disease effect significantly, short treating period, recurrence rate be low, remove Long-term taking medicine from. To various hyperthyroidism, can in March, cure. To thyroid adenoma, thyroid cyst and endemicgoiter etc., Can in February, cure (except the hypothyroidism patient).
Clinical observation 218 routine patients (comprising hyperthyroidism, thyroid tumor, thyroid cyst and endemic goiter), male 49 people wherein, women 169 people, minimum 17 years old of age, maximum 52 years old, 33.8 years old mean age.The course of disease is the longest 20 years, and is the shortest 5 months.After taking this preparation, 28 days the shortest courses of treatment, 3 months the longest courses of treatment.Total effective rate 98.6%, healing rate 90.8%, relapse rate only was 1.8% in invalid 1.4%, 5 year.
2, the present invention is a Chinese patent medicine preparation, and no chemical constituent and additive have no side effect to human body.The margin of safety experiment shows, takes this preparation of 200 times of concentration to rat, does not see intoxicating phenomenon.Take this preparation of 20 times of concentration continuous February for rabbit and Canis familiaris L., do not see the cumulative toxicity reaction.
3, Chinese medicine preparation of the present invention is treated various hyperthyroidism, thyroid tumor, thyroid cyst and endemic goiter merging antithyroid drug and is used the consumption and the untoward reaction that can obviously reduce antithyroid drug.
Claims (1)
1. the compound Chinese medicinal preparation that can treat hyperthyroidism, thyroid tumor, thyroid cyst and endemic goiter, the raw material that it is characterized in that making active ingredient is pressed column weight amount percentage ratio and is:
Sargassum 10%~30% Thallus Laminariae (Thallus Eckloniae) 10%~30% Spica Prunellae 10%~30%
Semen Sinapis Albae 10%~30% Rhizoma Dioscoreae Bulbiferae 10%~30% Bulbus Fritillariae Thunbergii 10%~30%
Herba Taraxaci 10%~30% Radix Salviae Miltiorrhizae 10%~30%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100960524A CN100374139C (en) | 2005-09-22 | 2005-09-22 | Chinese medicine compound preparation for treating hyperthyoidism |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100960524A CN100374139C (en) | 2005-09-22 | 2005-09-22 | Chinese medicine compound preparation for treating hyperthyoidism |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1781536A CN1781536A (en) | 2006-06-07 |
CN100374139C true CN100374139C (en) | 2008-03-12 |
Family
ID=36772408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100960524A Expired - Fee Related CN100374139C (en) | 2005-09-22 | 2005-09-22 | Chinese medicine compound preparation for treating hyperthyoidism |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100374139C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104547831A (en) * | 2015-02-09 | 2015-04-29 | 王秋霞 | Qi-supplementing yin-nourishing medicinal liquor for patients suffering from hyperthyroidism and preparation method of qi-supplementing yin-nourishing medicinal liquor |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103432476B (en) * | 2013-08-17 | 2015-04-15 | 张群 | Composition consisting of effective traditional Chinese medicine parts and used for treating hyperthyroidism |
CN103432333B (en) * | 2013-08-17 | 2015-04-15 | 张群 | Composition consisting of effective traditional Chinese medicine parts and used for treating hypothyroidism |
CN104042997A (en) * | 2014-06-22 | 2014-09-17 | 上海浦东高星生物技术研究所 | Hyperthyroidism treating pills |
CN105287901A (en) * | 2015-11-27 | 2016-02-03 | 黄德禄 | Traditional Chinese medicine pill for treating thyrophyma |
CN106075008B (en) * | 2016-06-15 | 2020-02-07 | 山东仙河药业有限公司 | Selfheal granules and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1156598A (en) * | 1996-02-07 | 1997-08-13 | 程先敏 | Medicine for treating thyreoidism |
CN1294015A (en) * | 1999-10-26 | 2001-05-09 | 马俊杰 | Medicine for treating thyroid enlargement and thyroidism |
-
2005
- 2005-09-22 CN CNB2005100960524A patent/CN100374139C/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1156598A (en) * | 1996-02-07 | 1997-08-13 | 程先敏 | Medicine for treating thyreoidism |
CN1294015A (en) * | 1999-10-26 | 2001-05-09 | 马俊杰 | Medicine for treating thyroid enlargement and thyroidism |
Non-Patent Citations (1)
Title |
---|
理气消瘿汤治疗甲亢34例. 李桂芳,李洁,韩淑芬.辽宁中医学院学报,第7卷第3期. 2005 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104547831A (en) * | 2015-02-09 | 2015-04-29 | 王秋霞 | Qi-supplementing yin-nourishing medicinal liquor for patients suffering from hyperthyroidism and preparation method of qi-supplementing yin-nourishing medicinal liquor |
Also Published As
Publication number | Publication date |
---|---|
CN1781536A (en) | 2006-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100374139C (en) | Chinese medicine compound preparation for treating hyperthyoidism | |
CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
CN101843694B (en) | Chinese medicament for treating chronic hepatitis | |
CN105381132A (en) | Drug for treating thyroid nodule | |
CN103055198A (en) | Medicine for treating diabetes mellitus and preparation method thereof | |
CN101249184B (en) | Medicine for treating osteoproliferation as well as its preparation method | |
CN102940782B (en) | Chinese medicinal composition for reducing blood sugar | |
CN101417100B (en) | Medicine for treating secondary lung tuberculosis and preparation method thereof | |
CN1772091A (en) | Rhinitis treating Chinese medicine prepn | |
CN1182866C (en) | Medicinal liquor for curing rheumatism and traumatic injuries | |
CN101336990B (en) | Medicine for treating cholecystitis | |
CN101843704B (en) | Chinese medicament for treating chronic hepatitis | |
CN101940699B (en) | Traditional Chinese medicine for assisting in treating liver cancer | |
CN100488547C (en) | Pharmaceutical composition for treating tinea and complication thereof | |
CN101757223B (en) | Externally-applied traditional Chinese medicine for treating psoriasis | |
CN109010549A (en) | Synthetism expelling wind and activating blood flow pain relieving ointment and preparation method thereof | |
CN103028088B (en) | Traditional Chinese medicine composition for treating coronary heart disease and angina | |
CN102319390B (en) | Medicament for treating chronic cholecystitis | |
CN101979073A (en) | Medicament for soothing liver and regulating Qi | |
CN101862435A (en) | Chinese medicament for treating gastritis | |
CN103356957B (en) | Medicine for treating stomach cancer and preparation method thereof | |
CN101983653B (en) | Drug for treating lumbocrural pain and preparation method thereof | |
CN103006942B (en) | Traditional Chinese medicine for treating osteoporosis by utilizing acer mono | |
CN114788854A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
CN101040919B (en) | Chinese traditional medicine for treating cholecystitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Liu Wenlong Document name: Correction notice |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080312 Termination date: 20091022 |